BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12007948)

  • 1. An Internet-ready database for prospective randomized clinical trials of high-dose-rate brachytherapy for adenocarcinoma of the prostate.
    Devlin PM; Brus CR; Kazakin J; Mitchell RB; Demanes DJ; Edmundson G; Gribble M; Gustafson GS; Kelly DA; Linares LA; Martinez AA; Mate TP; Nag S; Perez CA; Rao JG; Rodriguez RR; Shasha D; Tripuraneni P
    Int J Radiat Oncol Biol Phys; 2002 May; 53(1):104-15. PubMed ID: 12007948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.
    Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.
    Stromberg J; Martinez A; Gonzalez J; Edmundson G; Ohanian N; Vicini F; Hollander J; Gustafson G; Spencer W; Yan Di
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):161-71. PubMed ID: 7543891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
    Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.
    Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D
    Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Which modality for prostate brachytherapy?].
    Bossi A
    Cancer Radiother; 2010 Oct; 14(6-7):488-92. PubMed ID: 20724190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
    Nickers P; Thissen B; Jansen N; Deneufbourg JM
    Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated results of high-dose rate brachytherapy and external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
    Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R
    Int Braz J Urol; 2008; 34(3):293-301. PubMed ID: 18601759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of high-dose rate prostate brachytherapy dose distributions with iridium-192, ytterbium-169, and thulium-170 sources.
    Krishnamurthy D; Weinberg V; Cunha JA; Hsu IC; Pouliot J
    Brachytherapy; 2011; 10(6):461-5. PubMed ID: 21397569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
    Krauss DJ; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Gustafson GS
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):98-106. PubMed ID: 27979460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of dosimetry between high-dose-rate and permanent prostate implant brachytherapies in patients with prostate adenocarcinoma.
    Wang Y; Sankreacha R; Al-Hebshi A; Loblaw A; Morton G
    Brachytherapy; 2006; 5(4):251-5. PubMed ID: 17118319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
    Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models.
    King CR
    Brachytherapy; 2002; 1(4):219-26. PubMed ID: 15062170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
    Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
    Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of three-dimensional radiation therapy planning tools and intraoperative ultrasound to evaluate high dose rate prostate brachytherapy implants.
    Kini VR; Edmundson GK; Vicini FA; Jaffray DA; Gustafson G; Martinez AA
    Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):571-8. PubMed ID: 10078639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.